Merck Expects 2024 Sales Of $63.6B-$64.1B Compared To Prior Guidance Of $63.4B-$64.4B And Consensus Of $64.162B
Portfolio Pulse from Benzinga Newsdesk
Merck has updated its 2024 financial outlook, slightly adjusting its sales guidance to $63.6B-$64.1B from the previous $63.4B-$64.4B, and below the consensus of $64.162B. The company also revised its non-GAAP EPS to $7.72-$7.77 from $7.94-$8.04.
October 31, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck's updated 2024 financial outlook shows a slight decrease in sales guidance and non-GAAP EPS, which may impact investor sentiment negatively in the short term.
Merck's updated guidance indicates a slight decrease in expected sales and non-GAAP EPS compared to prior guidance and consensus estimates. This could lead to a negative short-term reaction from investors as expectations are adjusted downward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100